Table 1.
List of monoclonal antibodies evaluated.
Table 2.
ELISA binding results to different spike protein variants.
Table 3.
Microneutralization analysis on various antibodies.
Fig 1.
The results of the viral variant testing. Heat map represents activity as measured by the average ratio of the mutation IC50/wild type (D614G). Ratios are provided in the Figures. The average is calculated from multiple experiments so specific mutation IC50 and WT IC50 are not provided. IC50 (dark grey represents <0.3; light grey represents 0.3–5.0; yellow represents 5.0–10.0; orange represents 10.0–50.0; red represents >50.0). (A) Neutralization results against VOCs; (B) Neutralization results against a panel of mutant variants of the non-RBD, (C) Neutralization results against a panel of mutant variants of the RBD.
Fig 2.
Binding of the monoclonal antibody variants to Fc receptors.
The bar graphs present the overall binding of the monoclonal antibody variants to the indicated Fc receptor represented as the area under the curve calculated from the dilution curves presented in S1 Fig. Data are presented as the mean AUC ± standard deviation from two independent experiments. (A) FCGR2A 131H; (B) FCGR2A 131R; (C) FCGR2B; (D) FCGR3A 158F; (E) FCGR3A 158V; (F) FCGR3B; (G) FCRN pH6; (H) FCRN pH 7.4. The Ebola virus GP–specific antibody KZ52 was used as the irrelevant antibody. Significance was calculated using a one-way ANOVA with post hoc Holm-Šídák’s multiple comparisons test. *: p ≤ 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Fig 3.
Extra-neutralizing functional activity of the monoclonal antibody variants.
The data are presented both as bar graphs representing the overall activity of the monoclonal antibody variants in the indicated functional assays represented as the area under the curve calculated from the individual dilution curves presented in S2 Fig. Data are presented as the mean AUC ± standard deviation from two independent experiments. For assays using primary cells, cells isolated from two independent donors were used. (A) Antibody-dependent cellular phagocytosis; (B) antibody-dependent neutrophil phagocytosis; (C) antibody-dependent cellular cytotoxicity; (D–F) antibody-dependent NK cell activation; (G) antibody-dependent complement deposition; (H) antibody-dependent mucin (MUC5A/C) binding; (I) antibody-dependent mucin (MUC5B) binding. The Ebola virus GP–specific antibody KZ52 was used as the irrelevant antibody. Significance was calculated using a one-way ANOVA with post hoc Holm-Šídák’s multiple comparisons test. *: p ≤ 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.